Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBITDA Margin (2018 - 2026)

10x Genomics' EBITDA Margin history spans 8 years, with the latest figure at 11.77% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1843.0% to 11.77% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.49%, a 2237.0% increase, with the full-year FY2025 number at 9.49%, up 2237.0% from a year prior.
  • EBITDA Margin hit 11.77% in Q4 2025 for 10x Genomics, up from 21.64% in the prior quarter.
  • Over the last five years, EBITDA Margin for TXG hit a ceiling of 17.42% in Q2 2025 and a floor of 61.7% in Q3 2023.
  • Historically, EBITDA Margin has averaged 26.36% across 5 years, with a median of 27.31% in 2024.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 35735bps in 2021 and later plummeted -4554bps in 2022.
  • Tracing TXG's EBITDA Margin over 5 years: stood at 12.97% in 2021, then decreased by -14bps to 14.78% in 2022, then tumbled by -103bps to 30.0% in 2023, then dropped by -1bps to 30.2% in 2024, then skyrocketed by 61bps to 11.77% in 2025.
  • Business Quant data shows EBITDA Margin for TXG at 11.77% in Q4 2025, 21.64% in Q3 2025, and 17.42% in Q2 2025.